Log In
BCIQ
Print this Print this
 

MAG1C

  Manage Alerts
Collapse Summary General Information
Company DBV Technologies S.A.
DescriptionReady--to-use standardized atopy patch-test using DBV's Viaskin patch technology
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPreclinical
Standard IndicationInfectious, Diagnostic
Indication DetailsDiagnose pediatric cow's milk allergy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$113.6M

$11.4M

$113.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/31/2016

$113.6M

$11.4M

$113.6M

Get a free BioCentury trial today